Commissioning success for Alpha's new cGMP biomanufacturing plant

Construction is complete on Alpha Biologics' new 5,000 sq metre mammalian cell biomanufacturing plant at Penang Biotech Park in Malaysia. The new $18m plant recently underwent extensive programmes of commissioning and QA tests before official hand-over. The plant was constructed to an FDA-approved design and is primarily dedicated to the production of mammalian cell secreted proteins such as monoclonal antibodies and recombinant proteins. Michelle Peake, Alpha's COO said:

"We're really pleased with the plant - the design and construction contractors have done a great job. Its been a long while coming, but its great to have it complete and open for business".

The plant was designed with innovative process capabilities allowing Alpha to significantly reduce manufacturing costs, while still ensuring full cGMP manufacturing compliance. This includes multiple isolation suites, combined stirred tank and perfusion technology, two separate DSP suites and separate final filtration/viral removal suites. Alpha believes that this will significantly increase productivity and shorten the manufacturing cycle, giving significant time and money savings to clients.

The company also has R&D and process development laboratories in Cambridge, UK.